key: cord-0327685-fzu9r11p
authors: Han, A. X.; Toporowski, A.; Sacks, J. A.; Perkins, M.; Briand, S.; van Kerkhove, M.; Hannay, E.; Carmona, S.; Rodriguez, B.; Parker, E.; Nichols, B. E.; Russell, C. A.
title: Low testing rates limit the ability of genomic surveillance programs to monitor SARS-CoV-2 variants: a mathematical modelling study
date: 2022-05-23
journal: nan
DOI: 10.1101/2022.05.20.22275319
sha: 02f5f170abebf6661e7cb15d6347be9a09dea9f3
doc_id: 327685
cord_uid: fzu9r11p

Background Genomic surveillance is essential for monitoring the emergence and spread of SARS-CoV-2 variants. SARS-CoV-2 diagnostic testing is the starting point for SARS-CoV-2 genomic sequencing. However, testing rates in many low- and middle-income countries (LMICs) are low (mean = 27 tests/100,000 people/day) and global testing rates are falling in the post-crisis phase of the pandemic, leading to spatiotemporal biases in sample collection. Various public health agencies and academic groups have produced recommendations on sample sizes and sequencing strategies for effective genomic surveillance. However, these recommendations assume very high volumes of diagnostic testing that are currently well beyond reach in most LMICs. Methods To investigate how testing rates, sequencing strategies and the degree of spatiotemporal bias in sample collection impact variant detection and monitoring outcomes, we used an individual-based model to simulate COVID-19 epidemics in a prototypical LMIC. Within the model, we simulated a range of testing rates, accounted for likely testing demand and applied various genomic surveillance strategies, including sentinel surveillance. Findings Diagnostic testing rates play a substantially larger role in monitoring the prevalence and emergence of new variants than the proportion of samples sequenced. To enable timely detection and monitoring of emerging variants, programs should achieve average testing rates of at least 100 tests/100,000 people/day and sequence 5-10% of test-positive specimens, which may be accomplished through sentinel or other routine surveillance systems. Under realistic assumptions, this averages to ~10 samples for sequencing/1,000,000 people/week. Interpretation For countries where testing capacities are low and sample collection is spatiotemporally biased, surveillance programs should prioritize investments in wider access to diagnostic testing to enable more representative sampling, ahead of simply increasing quantities of sequenced samples. Funding European Research Council, the Rockefeller Foundation, and the Governments of Germany, Canada, UK, Australia, Norway, Saudi Arabia, Kuwait, Netherlands and Portugal.

Background 24

Genomic surveillance is essential for monitoring the emergence and spread of SARS-CoV-2 25 variants. SARS-CoV-2 diagnostic testing is the starting point for SARS-CoV-2 genomic 26 sequencing. However, testing rates in many low-and middle-income countries (LMICs) are 27 low (mean = 27 tests/100,000 people/day) and global testing rates are falling in the post-crisis 28 phase of the pandemic, leading to spatiotemporal biases in sample collection. Various public 29 health agencies and academic groups have produced recommendations on sample sizes and 30 sequencing strategies for effective genomic surveillance. However, these recommendations 31 assume very high volumes of diagnostic testing that are currently well beyond reach in most 32

LMICs. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 23, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) higher testing rates in some HICs (Figure 1 ). Low testing rates lead to spotty information and 133 smaller virus specimen pools available for sequencing, resulting in strong sampling biases. 134

These factors can render efforts to monitor the emergence of new variants or prevalence of 135 existing variants highly unreliable. 136 137 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Here, we studied how different testing rates can impact genomic surveillance outcomes. 145

Specifically, we used an individual-based modelling framework to simulate concurrently-146 circulating wild-type SARS-CoV-2/Alpha-as well as Delta-/Omicron-like epidemics in 147

Zambia as a representative LMIC archetype. We then applied different genomic surveillance 148 sampling strategies (i.e., sources of sample collection and varying proportion of specimens to 149 sequence) to elucidate how testing, sequencing volumes and the degree of sampling bias 150 arising from sources of specimens jointly impact the timeliness of variant detection and the 151 accuracy of variant monitoring. 152 153 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Zambia. Briefly, PATAT creates an age-structured population, linking individuals within 160 contact networks of multi-generational households, schools, workplaces, and churches (i.e., 161 regular mass gatherings) (Table S1 ). Healthcare facilities (i.e., community clinics and tertiary 162 hospitals) where individuals with mild symptoms seek symptomatic testing and have their 163 virus specimens collected are simulated to approximate localized community structures based 164 on an empirical clinic-to-population ratio. Households are proximally distributed around 165 these facilities based on the given empirical distance distribution that correlates with 166 probabilities of symptomatic individuals seeking testing at clinics (Table S1) . (Table S1 ). Before simulating the two-variant epidemic, we first 181 calibrated the transmission probability parameter for the extant variant such that it would 182 spread in a completely susceptible population at ܴ = 2·5-3·0. We then assumed Alpha and 183

Omicron (BA.1) were more transmissible that the respective extant virus to achieve growth 184 rates of ~0·15/day and ~0·35/day respectively. 2,14 185 186 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275319 doi: medRxiv preprint For both sets of simulations, we assumed that 10% of the population had infection-acquired 187 immunity against the extant strain initially with some level of protection against infection by 188 the mutant virus (wild-type SARS-CoV-2: 80% protection against Alpha; 15 Delta: 20% 189 protection against Omicron 14 ). We also investigated the scenario where 40% of the 190 population had infection-acquired immunity as part of sensitivity analyses (see below). We 191 did not investigate scenarios involving vaccine-acquired immunity due to low vaccine uptake 192 in most LMICs. 16 for sequencing. We assumed that symptomatic individuals sought testing based on a 200 probability distribution of health services-seeking behaviour that inversely correlates with the 201 distance between the individual's household and the nearest healthcare facility (Table S1) second half of 2021, 18 we assumed 10% test positivity rate at the start and end of the 210 simulated epidemic, and 20% test positivity at its peak, linearly interpolating the rates 211 between these timepoints. We also assumed that false positive specimens could be sampled 212 based on reported Ag-RDT specificity of 98·9%. 10 213 214

We assumed that any specimens collected for genomic surveillance after positive detection 215 through Ag-RDT would be reflexively confirmed with PCR. We also assumed that all 216 symptomatic individuals who have severe symptoms require hospitalization, and are tested 217 separately from mild symptomatic persons who sought testing. Given that likely only ~10-218 20% of COVID-19 deaths in Zambia were tested for the disease in life, 19,20 we assumed that 219 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. For all strategies, we assumed that a proportion (1%-100%; in 2% increments between 1% 243 and 5%, in 5% increments between 5% and 100%) of positive specimens are collected daily 244 for sequencing. We also assumed that positive specimens sampled within each week for 245 sequencing are consolidated into a batch before they are referred for sequencing. Turnaround 246 time refers to the time between collection of each weekly consolidated batch of positive 247 specimens to the acquisition of its corresponding sequencing data. Since the within-host viral 248 loads of infected individuals were simulated, we assumed that only high-quality samples 249

where Ct values < 30 could be sequenced and that sequencing success rate is 80% as assumed 250 in other studies. 6 251 252 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. For each strategy and sequencing proportion, we performed 100 bootstrap simulations for 253 each epidemic simulation with a given test stock availability, thus totaling to 1,000 random 254 simulations for each set of variables (i.e., testing rate, sequencing proportion, and strategy). 255 256 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275319 doi: medRxiv preprint

We first applied current guidance from different stakeholder and academic groups on the 259 number of positive specimens to sequence to detect SARS-CoV-2 variants at low prevalence 260 (Table 1) 1-29 sequences per day to detect an Alpha-like variant based on 0·03% initial introduction for a population of 10,000 (assuming growth rate of 0·1/day) at 1% with 95% confidence.

We used the spreadsheet (https://github.com/HopkinsIDD/VOCsamplesize) provided and input appropriate parameters to obtain the recommendation relevant to the simulated epidemics.

• Assumes that the observed variant proportion in the positive specimens collected is representative of the circulating variant proportions among the infected population • Assumes asymptomatic patients are tested as well which may not be applicable for many LMICs where self-testing and asymptomatic community testing programs are currently rare. Widespread asymptomatic testing has also been substantially reduced in most HICs in the post-crisis phase of the pandemic. • Requires a large number of specimens that are randomly collected for assumption to hold true at low circulating variant proportions.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

To elucidate how SARS-CoV-2 testing rates and the proportion of positive specimens 295 sequenced impact the speed of variant detection, we simulated wild-type SARS-CoV-2/Alpha 296 and Delta/Omicron epidemics at different Ag-RDT availability ranging from 27 297 tests/100k/day to 1,000 tests/100k/day (Figure 3) . We assumed that specimens to be 298 sequenced are sampled on their collection day, and varied the proportion of positive 299 specimens to sample for sequencing each day between 1% and 100%. We analyzed the 300 impact of testing rates and sequencing proportions on the expected day when the first 301 specimen sampled for sequencing containing the variant was collected as a measure of 302 variant detection speed. In Figure 3 , we did not consider the time between sample collection 303 and sequencing nor the turnaround time to obtaining sequencing results as they would only 304 delay the actual day of variant detection by the assumed turnaround time. 305 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275319 doi: medRxiv preprint proportion (Figures 4 and S1) . At a testing rate of 27 tests/100k/day, the observed variant 343 proportion maximally differs from the true circulating proportion by >30% for both the Alpha 344 and Omicron variants and for more than 15% of the time, the proportional difference between 345 the observed and true variation was greater than 20%. Both the maximum absolute difference 346 and percentage of timepoints where the difference is >20% can be lowered to <20% and <5% 347 respectively if testing rate is increased to 100 or more tests/100k/day. 348 349 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275319 doi: medRxiv preprint 

Our findings show that the emphasis on the size of the sample referred for genomic 404 surveillance is misplaced if testing capacity is insufficient and sample sources are highly 405 spatiotemporally biased. As such, at the current mean rate of testing in LMICs (27 406 tests/100k/day), current guidance 5-8 on sequencing sample size estimation could likely lead to 407 later-than-predicted detection of novel variants at best or, at worst, leave new variants 408 undetected until they have infected a majority of a population. 409 410 Based on our work, we identified three major areas of improvement that should be prioritized 411 to enhance the robustness of genomic surveillance programs ( Figure 6 ). First, the most 412 substantial improvements are likely to come from increasing the mean testing rate in LMICs 413 from 27 tests/100k/day ( Figure 6A ) to at least 100 tests/100k/day ( Figure 6B ). Even if one 414 were to only doing sentinel surveillance at one tertiary facility, this increase in testing rate for 415 the catchment area of the facility would speed up variant detection by 1-2 weeks. 416 417 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275319 doi: medRxiv preprint

Genomic surveillance to combat COVID-19: 529 challenges and opportunities

SARS-CoV-2 lineage B.1.1.7 in England

SARS-CoV-2 Spike Mutations

the Second Wave of COVID-19 in Maharashtra, India. 534 Microorganisms 2021

Rapid epidemic expansion of the SARS-CoV-2 536

Omicron variant in southern Africa

Global disparities in SARS-CoV-2 genomic 538 surveillance

Sample Size Calculations for Variant 540

Surveillance in the Presence of Biological and Systematic Biases

Sequencing of SARS-CoV-2 -first update

Guidance for surveillance of SARS-CoV-2 variants: interim guidance

Second, the representativeness of a specimen pool for sequencing can be further improved by 434 expanding sampling coverage. In our model, variant detection was further sped up by 1-3 435 weeks by increasing the percentage of tertiary sentinel facilities sending the samples they had 436 collected for sequencing to 25% of facilities ( Figure 6C ). Additionally, in terms of prevalence 437 monitoring, if 25% of tertiary facilities sequenced 5% of all positive specimens they had 438 collected to detect and monitor an Alpha-like variant, the maximum absolute difference to 439 true circulating proportion is expected to decrease from >50% (assuming a single sentinel 440 facility) to no more than 20%. 441 442 Third, reducing turnaround time of sample referred for sequencing results in a 1:1 decrease in 443 time to new variant detection regardless of the proportion of sequenced samples, test 444 availability or sampling coverage ( Figure 6 ). These gains require scale up in sample transport 445 networks, access to sequencing machinery, trained personnel, and/or increases in numbers of 446 sequenced samples to make the most efficient use of each sequencing run. 447 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. After reducing spatiotemporal bias in the specimen pool through increased testing and 449 sampling coverage, sequencing up to 5-10% of the positive specimens collected would return 450 the greatest information gains while minimizing resource wastage. For an Alpha-like variant, 451 at 100 tests/100k/day with sampling from 25% of tertiary sentinel facilities for sequencing, 452 this amounts to an estimated 5-10 sequences per week averaged over a 90-day period per 453 1,000,000 people. If turnaround time is kept within one week, the variant would likely be 454 detected within one month at ~4% circulating proportion ( Figure 6D) . Similarly, at the same 455 testing rate, sampling coverage and turnaround time (i.e. average 5-11 sequences per week 456 per 1,000,000 people), an Omicron-like variant would be detected before the first month 457 since its introduction but at ~23% circulating proportion owing to its faster transmission 458 ( Figure S5 ). 459

Our findings here serve to inform expectations as genomic surveillance programs are being 461 developed and should be interpreted according to the public health objectives of each 462 program. If the objective is to serve as an early warning system for the emergence of new 463 variants of concern before they are likely to have spread widely, then all factors above are 464 essential and will likely require substantially more than 100 tests/100k/day. Critically, 465 determining that a new variant is a threat requires not only detection of the variant itself but 466 also the capacity to reliably monitor changes in its prevalence and potential clinical impact on 467 short timescales. The results presented here also inform the design of programs for the 468 sensitive and reliable detection of changes in variant prevalence. The authors are pleased to acknowledge that all computational work reported in this paper 512 was performed on the Shared Computing Cluster which is administered by Boston 513University's Research Computing Services (www.bu.edu/tech/support/research/). 514 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted May 23, 2022. ; https://doi.org/10.1101/2022.05.20.22275319 doi: medRxiv preprint